Rocket Pharmaceuticals announces closing of public offering and exercise of options
Rocket Pharma announces closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 675,000 additional shares of its common stock. Gross proceeds are expected to be $90.6 million. April 18, 2019